Favorable outcome of Epstein-Barr virus-associated B-cell lymphoproliferative disorder complicated by immunoglobulin G4-related disease treated with rituximab-based therapy: a case report by Koki Ueda et al.
CASE REPORT Open Access
Favorable outcome of Epstein-Barr virus-
associated B-cell lymphoproliferative
disorder complicated by immunoglobulin
G4-related disease treated with rituximab-based
therapy: a case report
Koki Ueda1, Kazuhiko Ikeda1,2*, Kazuei Ogawa1, Masumi Sukegawa1, Takahiro Sano1, Satoshi Kimura1,
Osamu Suzuki3, Yuko Hashimoto3 and Yasuchika Takeishi1
Abstract
Background: After acute infection of Epstein-Barr virus, Epstein-Barr virus-infected B cells survive but usually do not
show clonal proliferation. However, Epstein-Barr virus-infected B cells occasionally acquire a proliferative capacity that
provokes clonal lymphoproliferative disorders. We herein present a case with Epstein-Barr virus-infected CD30+ B cell
and immunoglobulin G4+ plasmacytoid cell proliferation in the lymph nodes, suggesting a pathological and
clinical interaction between Epstein-Barr virus-associated B-cell lymphoproliferative disorders and immunoglobulin
G4-related disease. Immunoglobulin G4-related disease has been recognized as a benign disease with proliferation of
IgG4-related disease+ plasmacytoid cells. Several studies have recently reported the coexistence of immunoglobulin
G4-related disease+ plasmacytoid cells with Epstein-Barr virus-infected B cells in lymph nodes in some immunoglobulin
G4-related disease cases. However, the pathogenic role of the clonal proliferation of Epstein-Barr virus-infected B cells
in immunoglobulin G4-related disease, as well as the treatments for patients with both Epstein-Barr virus-infected B
cells and immunoglobulin G4-related disease, have never been discussed.
Case Presentation: A 50-year-old Japanese man was referred to us for persistent fatigue and lymphadenopathy. His
blood examination showed elevated IgG4, and detected high levels of Epstein-Barr virus DNA. A lymph node biopsy
revealed IgG4+ plasmacytoid cells and infiltration of large lymphoid cells, which were positive for CD20, CD30,
Epstein-Barr virus-related late membrane protein 1, and Epstein-Barr virus-encoded RNA, and were negative for
IgG4. Based on the diagnosis of both Epstein-Barr virus-associated B-cell lymphoproliferative disorder and IgG4-
related disease, the patient received eight cycles of rituximab combined with cyclophosphamide and prednisolone,
which resulted in the complete disappearance of lymphadenopathy. Moreover, his serum IgG4 level was significantly
reduced, and plasma Epstein-Barr virus DNA became undetectable. Although prednisolone was transiently administered
in each cycle of immunochemotherapy, the therapeutic effect has persisted for Epstein-Barr virus-associated B-cell
lymphoproliferative disorder and IgG4-related disease as of 1 year after finishing treatment.
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Conclusions: In the present case, clinical presentation and pathological findings revealed that Epstein-Barr virus-
associated B-cell lymphoproliferative disorder coexisted with IgG4-related disease. Although several studies have
described the relationship between Epstein-Barr virus-infected B cells and IgG4-related disease, this is the first report of
a patient whose plasma Epstein-Barr virus DNA level, which correlated with the disease statuses of both diseases, was
monitored. Moreover, rituximab-based immunochemotherapy was highly effective for both diseases. Our findings are
suggestive for establishing a novel treatment strategy for IgG4-related disorders associated with chronic Epstein-Barr
virus infection.
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Background
Persistent infection of Epstein-Barr virus (EBV) in B
cells occasionally evokes a variety of lymphoproliferative
disorders (LPDs). These include malignant lymphomas
such as diffuse large B-cell lymphoma (DLBCL) and
Hodgkin’s lymphoma. However, polymorphous B-cell
LPDs resembling reactive lymphoid hyperplasia or
nodal/extranodal polymorphic LPD are also observed in
infected individuals [1, 2]. In most cases, after acute infec-
tion of EBV, the infected B cells continue to be present in
small quantities and do not usually give rise to LPD. How-
ever, systemic or localized immunodeficiency may trans-
form EBV-infected B cells into clonal or malignant status
[3]. Given that transformation of EBV-infected B cells
arises on the background of immunocompromised condi-
tions, it is conceivable that another disease caused by an
immunological disorder could coexist in the same lesion
as the EBV-associated B-cell LPDs.
Immunoglobulin (Ig) G4-related disease (IgG4-RD) is
a newly defined syndrome characterized by sclerosing
and mass-forming changes of various lymphoid and
non-lymphoid tissues. IgG4-RD are caused by invasion
of IgG4-producing plasma cells and/or B cells that lead
to fibroinflammatory conditions, and immunological dis-
order is thought to be a key factor of the pathogenesis of
IgG4-RD [4]. To date, only two reports have shown that
IgG4-RD may be associated with chronic infection of
EBV [2, 3]. Takahashi et al. recently described a single
case of concurrent IgG4-related lymphadenopathy and
EBV infection [5]. Subsequently, it was reported that 18
of 31 (58 %) IgG4-related lymphadenopathy specimens
harbored EBV-encoded RNA (EBER)+ cells, whereas
EBER+ cells were detected in only 4 of 22 (18 %) reactive
lymphoid hyperplasia specimens [6]. Although these
reports shed light on the morphological coexistence
of EBV-infected B cells and IgG4-producing cells in
the lymph nodes, the interaction between the sys-
temic status of EBV infection and IgG4-RD remains
to be elucidated.
In EBV-associated B-cell LPDs, neoplastic EBV-positive
cells often co-express CD30 [7, 8]. The combination of
CD30 expression and EBV infection in neoplastic B cells
results in poor outcome in EBV-associated B-cell LPDs,
most evidently in DLBCL [9]. Here, we report a case of
successful treatment with rituximab-combined immuno-
chemotherapy in a patient with IgG4-RD complicated
with polymorphous EBV-associated B-cell LPD, and dis-
cuss the pathogenesis and treatment of the disease.
Case presentation
A 50-year-old Japanese man was referred to our hospital
with fatigue and swelling of the parotid glands and in-
guinal nodes. His blood count was normal, and no major
organ dysfunction was detected by biochemical tests.
However, markedly elevated values of serum IgG (6188
mg/dL; normal range 870–1700 mg/dL) and IgG4 (2970
mg/dL; normal range 4.8–105 mg/dL) were noted.
Soluble-IL2 receptor (sIL2-R) (2130 U/mL; normal range
124–466 U/mL) was also increased. A high level of EBV
DNA was detected in the serum plasma (3.0 × 104
copies/mL), with elevated IgG antibodies to EBV viral
capsid antigen (VCA) (detectable at a 1:1280 titer)
and early antigen (EA) (detectable at a 1:160 titer).
Anti-EB nuclear antigen (EBNA) antibody was also
detected (detectable at a 1:80 titer), indicating a chronic
active EBV infection. Antibodies to hepatitis B virus, hepa-
titis C virus, human immunodeficiency virus, and human
T-cell lymphotrophic virus type I were negative. Systemic
positron emission tomography-computed tomography
(PET-CT) with fluorodeoxy glucose (FDG) revealed an
uptake of FDG in our patient’s enlarged parotid glands
and kidneys, as well as the cervical, mediastinal, and
inguinal lymph nodes (Fig. 1h). An inguinal lymph
node biopsy was performed. Histologically, the lymph
node architecture was almost preserved except for an ex-
panded interfollicular zone. Both small- or medium-sized
plasmacytoid cells and large lymphoid cells proliferated in
the interfollicular zone with formations of small vessels
(Fig. 1a). Most plasmacytoid cells were positive for IgG/
IgG4 and CD20 (Fig. 1b, c, d), fulfilling the histological cri-
teria for IgG4-related disease [10]. In contrast, large lymph-
oid cells were positive for CD20 and CD30 (Fig. 1d, e).
These large lymphoid cells were also positive for latent
membrane protein (LMP)-1 and EBER (Fig. 1f, g),
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indicating latency III infection of EBV [11]. Since EBV+
LPDs consist of EBV-associated reactive lymphoid hyper-
plasia, EBV-associated polymorphic lymphoproliferative
disease, and EBV+ DLBCL [12], we evaluated the re-
arrangement of Ig heavy- and light-chains by polymerase
chain reaction. This analysis did not show clonal re-
arrangement, suggesting that the B-cell proliferation of this
patient belongs to a subtype such as EBV-associated poly-
morphic lymphoproliferative disease rather than EBV+
DLBCL. Thus, diagnoses of both IgG4-RD and poly-
morphous EBV-associated B-cell LPD were made. On the
other hand, there was no evidence of EBV infection in the
parotid gland specimen, although it was heavily infiltrated
with IgG/IgG4-positive plasmacytoid cells, but not large
lymphoid cells. Ig-kappa+ cells and Ig-lambda+ cells were
similarly distributed, indicating polyclonal proliferation of
these plasmacytoid cells. Thus, we worked up his baseline
immunodeficiency, which can potentially contribute to the
development of IgG4-RD or chronic EBV infection. How-
ever, the proportions of CD3+, CD4+, and CD8+ lympho-
cytes were normal, and a review of the patient’s medical
records did not show any evidence of genetic or inherited
immunodeficiency in his family.
Considering the massive proliferation of EBV-
infected large B cells with the IgG4+ plasmacytoid
cells, he was treated with rituximab (375 mg/m2), oral
cyclophosphamide (100 mg/day for 5 days), and pred-
nisolone (40 mg/day for 5 days) biweekly. After eight
courses of therapy, FDG uptake disappeared and the
size of the parotid gland, as well as the lymph nodes,
was normalized in PET-CT (Fig. 1i). In addition,
plasma EBV DNA became undetectable and sIL2-R
(395 U/mL) and IgG4 (655 mg/dL) were reduced
(Fig. 2). Despite our recommendation, our patient did
not receive maintenance therapy, because he was con-
cerned about potential adverse reactions due to the
consecutive administration of steroids.
Discussion
There have been few studies describing the relationship
between IgG4-RD and EBV infection [5, 6]. According
to these studies, EBV is more frequently positive in
lymph nodes than in the extranodal lesion of IgG4-RD.
Similarly, in the present case, EBV-infected CD20+
lymphoid cells were found only in the inguinal lymph
nodes, not in the parotid glands. Therefore, it may be
better to evaluate lymph nodes rather than extranodal
tissues to detect EBV-infected cells in IgG4-RD, even if
IgG4-RD is already evident in extranodal tissues. In
addition, our patient did not show any evidence of im-
munodeficiency. It is well known that immunodeficient
conditions that correlate with clonal B-cell proliferation
Fig. 1 Histological, immunohistochemical and imaging findings of the case. a Hematoxylin and eosin staining of the inguinal node (×400). In the a, f, g,
plasmacytoid cells are indicated by large arrows, and large lymphoid cells are indicated by small arrows. b Immunoglobulin G, c immunoglobulin G4,
d CD20, e CD30, f latent membrane protein 1, g Epstein-Barr virus-encoded RNA in situ hybridization staining. h Fluorodeoxy glucose positron
emission tomography-computed tomography at the diagnosis. i Fluorodeoxy glucose positron emission tomography-computed tomography
after treatment
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include ageing, posttransplant status, and HIV infection;
however, recent reports [1, 13] have shown that EBV+ B
cell neoplasms often occur in young patients without
any known immunodeficiency. The etiology of EBV+ B-
cell proliferation in these patients remains unknown,
although a tolerogenic immune state has been reported
as a possible cause [13].
IgG4-RD is usually treated by administration of corti-
costeroids [14], but a standard treatment has not been
established for patients who are resistant to corticoste-
roids or require long-term administration of high doses
of corticosteroids. It has also been reported that rituxi-
mab is effective for some patients with IgG4-related
disease, including steroid-resistant cases [15, 16]. Ritux-
imab probably depletes B cells as a precursor to IgG4-
producing plasmacytoid cells [16, 17]. In addition, the
fact that 58 % of cases with IgG4-related lymphadenop-
athy harbor EBV-infected B cells [6] gives rise to the
possibility that IgG4-RD is often unexpectedly affected
by EBV infection. These EBV-infected cells can be tar-
geted by rituximab if they possess CD20. In accordance
with this information, we administered rituximab-based
immunotherapy with the expectation of targeting both
IgG4-RD and B-cell LPD. However, it remains unclear
whether these EBV-infected B cells acquire clonality
and dominancy that arises in IgG4-producing plasma-
cytoid cells, or B-cell neoplasms such as DLBCL. In the
present case, the clonality of EBV-infected B cells was
not clear, but plasma EBV DNA was detected at high
levels with high titers of EBV VCA and EA antibodies,
indicating chronic EBV infection. It is well known that
such EBV-infected B cells can develop B-cell LPDs with
both CD20 and CD30 expression in immunodeficient
conditions such as aged, posttransplant, or HIV virus-
infected status [18–20]. Thus, the fact that large lymphoid
CD20+ cells in the present case co-expressed CD30 may
suggest an immunodeficient condition in which the
etiologic role of IgG4-producing plasmacytoid cells is
unknown. Of note, older patients with EBV-associated
DLBCL and CD30 expression have a very poor outcome
[9]; however, rituximab-combined immunochemotherapy
successfully eradicated the EBV-infected cells in our
patient, as shown by the EBV DNA level.
EBV-infected germinal center B cells are considered to
be the origin of EBV-related B-cell LPD [3]. In our pa-
tient, EBER+ cells proliferated in the interfollicular zone,
similar to cases with EBV-related B-cell LPD. Thus, we
decided to treat this patient with rituximab, because the
eradication of EBV is reported to be important for a
favorable prognosis in EBV-related B-cell LPD [21]. It
seems that rituximab is effective for both CD20+ large
lymphoid cells and IgG4-producing plasmacytoid cells in
our patient, because rituximab-combined treatment re-
sulted in complete disappearance of nodal and extrano-
dal tumors with reduction of the serum plasma EBV
DNA level, as serum IgG4 remains to be detected at a
drastically decreased level. Notably, although our patient
was administered corticosteroid transiently, the thera-
peutic effect has persisted as of 1 year after stopping cor-
ticosteroid treatment. We believe that rituximab was
highly effective in part by eradicating the EBV-infected B
cells, because the reduction of lymphadenopathy was
much more extreme than extranodal lesions in most







Fig. 2 Clinical course of the patient. R-CP indicates immunochemotherapy with rituximab, cyclophosphamide and prednisolone; sIL2R, soluble
interleukin 2 receptor; IgG4, immunoglobulin G4; EBV, Epstein-Barr virus
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IgG4-related disease without evaluation for EBV infec-
tion [16]. However, in our case, extranodal lesions with-
out evidence of EBV infection also responded to the
rituximab therapy. The mechanism of the response is
unclear, although changes in systemic immune function
caused by eradication of EBV might have contributed to
the reconstitution of extranodal lesions. The role of
rituximab in the treatment of IgG4-RD with EBV-
infected B cells should be further investigated in both
clinical trials and basic studies.
It has been reported that an elevated sIL2R value
(>1500 U/mL) indicates poor prognosis in a variety of B-
cell lymphomas [22]. In our case, the sIL2R value was
2130 U/mL, which dropped to 395 U/mL after the treat-
ment, possibly corresponding to the clinical effect of
treatment with rituximab. However, the role of sIL2R
elevation in EBV+ B-cell LPD should be studied further
in the future, although the induction of T cells by
tumor-associated macrophages has been implicated as a
cause of such sIL2R elevation in B-cell lymphomas [22].
Conclusions
Our case may contribute to understanding the associ-
ation between IgG4-RD and EBV infection, and the de-
velopment of a novel therapeutic strategy for IgG4-RD.
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